CTIS2024-514122-23-00招募中1 期
Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL)
Association International Extranodal Lymphoma Study Group (IELSG)0 个研究点目标入组 24 人开始时间: 2024年5月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Ability to understand and willingness to sign a written informed consent, Adequate kidney and liver function, Adequate coagulation parameters, Women with childbearing potential who are using highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and for at least 3 months after the last IMP dose, Men who agree not to father a child during trial treatment and for at least 3 months after the last IMP dose, Patient able and willing to swallow trial drugs as whole capsule, Histologically confirmed diagnosis of MZL, Disease refractory to or in first or greater relapse after prior systemic therapy, In need of treatment disease satisfying the following criteria: • EMZL: symptomatic lymphoma or with other treatment indications (overt progression, deep invasion, bulky disease, impending organ damage, patient preference), symptomatic disseminated disease, contraindications to radiotherapy (RT), failure after antibiotics or after local therapy, • SMZL: presence of progressive or symptomatic splenomegaly and/ or any progressive cytopaenias, • NMZL: B symptoms, deterioration of peripheral blood counts due to lymphoma infiltration of the bone marrow, rapid enlargement of lymph nodes or compression of vital organs by bulky disease, Measurable or non-measurable lesions where the response is nevertheless evaluable by non-imaging means (e.g., gastric or bone marrow infiltrations), Ann Arbor Stage I-IV (Appendix A), ECOG performance status of 0, 1 or 2 with no deterioration over the previous 2 weeks prior to registration, Age = 18 years, Absolute neutrophil count (ANC) = 1.000/mm3 and platelets = 100.000/mm3, unless these abnormalities are related to bone marrow infiltration or to hypersplenism
排除标准
- •History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: a. Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the prostate at any time prior to study, b. Other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for =3 years without further treatment, Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML), Concomitant diseases that require anticoagulant therapy with warfarin or phenoprocoumon or other vitamin K antagonists and patients treated with dual anti-platelet therapy, Malabsorption syndrome or other condition that precludes enteral route of administration, Known hypersensitivity to trial drugs or to any component of the trial drugs, Concomitant treatment with strong CYP3A inducers or inhibitors, Treatment with proton pump inhibitors. Subjects receiving proton pump inhibitors who switch to antacids are eligible for enrollment to this study, Concurrent participation in another therapeutic clinical trial, History of or ongoing confirmed central nervous system (CNS) lymphoma, Patients who received any IMP within 30 days or 5 half-lives (whichever is shorter) before the first dose of the study IMP, Patients who received a live virus vaccination within 28 days of the first IMP dose, Any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment, Pregnant or breastfeeding women, Active human immunodeficiency virus (HIV) or active chronic hepatitis C or hepatitis B virus infection. Patients positive for hepatitis B core antibody (HBcAb) will be eligible if they are negative for HBV-DNA, Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with > 20 mg daily of prednisone dose or equivalent, Major surgery and any systemic anti-cancer treatment within 3 weeks prior to registration. If patients had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first IMP dose, Prior exposure to a BTK inhibitor or CD19-targeted therapy, Steroid therapy for anti-neoplastic intent, Severe or uncontrolled cardiovascular diseases, History of cerebrovascular accident or intracranial hemorrhage within 6 months prior to registration and known bleeding disorders (e.g., von Willebrand's disease or hemophilia)
研究者
相似试验
进行中（未招募）
1 期
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphomaMarginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapyMedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004396-38-ATIELSG - International Extranodal Lymphoma Study Group24
进行中（未招募）
1 期
Study of acalabrutinib and tafasitamab in patients with marginal zone lymphomaMarginal Zone Lymphomas refractory to or in first or greater relapse after prior systemic therapyMedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004396-38-ITIELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP24
进行中（未招募）
1 期
A phase Ib/II combination trial of acalabrutinib with standard R-CHOP chemotherapy in patients with diffuse large B-cell lymphomaDiffuse large B-cell lymphomas (most common type of non-Hodgkins lymphoma)MedDRA version: 19.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003213-18-GBniversity Hospital Southampton NHS Foundation Trust39
招募中
不适用
Acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphomaKCT0003724Seoul National University Hospital66
进行中（未招募）
1 期
A study of Acalabrutinib alone, or in combination with Rituximab and Lenalidomide for subjects with B-cell Non Hodgkin LymphomaB-cell Non-Hodgkin LymphomaMedDRA version: 21.1Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000111-84-ITACERTA PHARMA BV120